{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:24:15Z","timestamp":1754162655662,"version":"3.41.2"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100008143","name":"Oregon National Primate Research Center","doi-asserted-by":"publisher","award":["P51 OD011092"],"award-info":[{"award-number":["P51 OD011092"]}],"id":[{"id":"10.13039\/100008143","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Drug resistance and intolerance of dolutegravir-containing antiretroviral therapy (ART) are rising in low- and middle-income countries, resulting in a potentially increased use of doravirine-containing ART use. There are knowledge gaps regarding doravirine and hormonal contraceptive drug\u2013drug interactions among women living with human immunodeficiency virus (HIV).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a 5-parallel-group, prospective pharmacokinetic study among women living with HIV aged 18\u201345 years in Johannesburg, South Africa, between November 2021 and February 2024. We included a sixth, historical comparator group from a Kenyan study. After a \u22656-week lead-in period with doravirine-containing ART, participants initiated injectable medroxyprogesterone acetate (MPA), implantable etonogestrel (ENG), or nonhormonal intrauterine device contraception and were observed every 2\u20134 weeks for an additional 12 or 24 weeks. We analyzed serum MPA and ENG and plasma doravirine or dolutegravir concentrations per visit, using validated liquid chromatography\u2013mass spectrometry assays. We assessed log-transformed concentrations of each drug with geometric mean ratios (90% confidence intervals) and a multivariate model adjusted for age and body mass index. We described safety, tolerability, and effectiveness (HIV RNA &amp;lt;40 copies\/mL) of doravirine-containing ART.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 128 participants are included in this analysis. There were no significant reductions in the MPA, ENG, or doravirine concentrations. A total of 8 (3%) adverse events grade \u22652 were considered attributable to doravirine-containing ART and 22 (8%) to the contraceptive method. ART satisfaction was 100%, and viral suppression at study exit ranged from 86% to 96%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We found no detrimental bidirectional drug\u2013drug interactions and few adverse events between doravirine and hormonal contraceptives.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf196","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T07:44:51Z","timestamp":1744357491000},"page":"79-89","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetic and Clinical Associations Between Doravirine-Containing Antiretroviral Therapy and Injectable and Implantable Hormonal Contraceptive Methods Among Women Living With Human Immunodeficiency Virus in South Africa"],"prefix":"10.1093","volume":"232","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9893-5856","authenticated-orcid":false,"given":"Rena C","family":"Patel","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham , Birmingham, Alabama ,","place":["USA"]},{"name":"Department of Epidemiology, University of Alabama at Birmingham , Birmingham, Alabama ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3206-9666","authenticated-orcid":false,"given":"Nkosiphile","family":"Ndlovu","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Wits RHI, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Maheria","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham , Birmingham, Alabama ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5237-5885","authenticated-orcid":false,"given":"Reolebogile","family":"Kgoa","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Wits RHI, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Kew","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Wits RHI, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"La-Donna","family":"Kapa","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Wits RHI, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3881-2704","authenticated-orcid":false,"given":"Krishnaveni","family":"Reddy","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Wits RHI, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1332-4333","authenticated-orcid":false,"given":"Merusha","family":"Govindasami","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Wits RHI, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nomasonto","family":"Matswake","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Wits RHI, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4203-6298","authenticated-orcid":false,"given":"Nompumelelo","family":"Sigcu","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Wits RHI, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Seedat","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Wits RHI, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lerato","family":"Shale","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Wits RHI, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nashon","family":"Yongo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham , Birmingham, Alabama ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6732-9263","authenticated-orcid":false,"given":"Shukri A","family":"Hassan","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham , Birmingham, Alabama ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommy L","family":"Williams","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham , Birmingham, Alabama ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3383-9297","authenticated-orcid":false,"given":"David W","family":"Erikson","sequence":"additional","affiliation":[{"name":"Endocrine Technologies Core, Oregon National Primate Research Center, Oregon Health and Science University , Beaverton, Oregon ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9406-693X","authenticated-orcid":false,"given":"Kimberly K","family":"Scarsi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science; University of Nebraska Medical Center , Omaha, Nebraska ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0052-5830","authenticated-orcid":false,"given":"Thesla","family":"Palanee-Phillips","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Wits RHI, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]},{"name":"Department of Epidemiology, School of Public Health, University of Washington , Seattle, Washington ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"volume-title":"Global HIV statistics\u2014fact sheet","year":"2021","author":"Joint United Nations Programme on HIV\/AIDS (UNAIDS)","key":"2025073007425481100_jiaf196-B1"},{"key":"2025073007425481100_jiaf196-B2","doi-asserted-by":"crossref","first-page":"e019979","DOI":"10.1136\/bmjopen-2017-019979","article-title":"Prevalence and determinants of unplanned pregnancy in HIV-positive and HIV-negative pregnant women in Cape Town, South Africa: a cross-sectional study","volume":"8","author":"Iyun","year":"2018","journal-title":"BMJ Open"},{"issue":"Suppl 1","key":"2025073007425481100_jiaf196-B3","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/01.aids.0000363785.73450.5a","article-title":"Benefits and costs of expanding access to family planning programs to women living with HIV","volume":"23","author":"Halperin","year":"2009","journal-title":"AIDS"},{"key":"2025073007425481100_jiaf196-B4","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/QAD.0000000000001392","article-title":"Drug interactions between hormonal contraceptives and antiretrovirals","volume":"31","author":"Nanda","year":"2017","journal-title":"AIDS"},{"key":"2025073007425481100_jiaf196-B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14656566.2017.1378345","article-title":"Current and future contraceptive options for women living with HIV","volume":"19","author":"Patel","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"2025073007425481100_jiaf196-B6","doi-asserted-by":"crossref","first-page":"837358","DOI":"10.3389\/fgwh.2022.837358","article-title":"The effect of integration of family planning into HIV services on contraceptive use among women accessing HIV services in low and middle-income countries: a systematic review","volume":"3","author":"Grant-Maidment","year":"2022","journal-title":"Front Glob Womens Health"},{"key":"2025073007425481100_jiaf196-B7","first-page":"2021","article-title":"Pregnancies among women living with HIV using contraceptives and antiretroviral therapy in western Kenya: a retrospective, cohort study","volume":"178","author":"Patel","year":"2021","journal-title":"BMC Med"},{"key":"2025073007425481100_jiaf196-B8","doi-asserted-by":"crossref","first-page":"21396","DOI":"10.7448\/IAS.20.1.21396","article-title":"Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines","volume":"20","author":"Patel","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"2025073007425481100_jiaf196-B9","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1186\/s12889-019-7312-1","article-title":"Perspectives on contraceptive implant use in women living with HIV in Cape Town, South Africa: a qualitative study among primary healthcare providers and stakeholders","volume":"19","author":"Brown","year":"2019","journal-title":"BMC Public Health"},{"volume-title":"Updated recommendations on service delivery for the treatment and care of people living with HIV","year":"2021","author":"World Health Organization (WHO)","key":"2025073007425481100_jiaf196-B10"},{"author":"World Health Organization (WHO).","key":"2025073007425481100_jiaf196-B11"},{"key":"2025073007425481100_jiaf196-B12","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1056\/NEJMoa1905230","article-title":"Neural-tube defects and antiretroviral treatment regimens in Botswana","volume":"381","author":"Zash","year":"2019","journal-title":"N Engl J Med"},{"key":"2025073007425481100_jiaf196-B13","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/cid\/ciab1006","article-title":"Viral load status before switching to dolutegravir-containing antiretroviral therapy and associations with HIV treatment outcomes in sub-Saharan Africa","volume":"75","author":"Romo","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025073007425481100_jiaf196-B14","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae321","article-title":"Dolutegravir resistance in African programmatic settings among patients with failure of dolutegravir-based ART","volume":"11","author":"Murphy","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2025073007425481100_jiaf196-B15","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/s41591-023-02763-0","article-title":"HIV drug resistance to integrase inhibitors in low- and middle-income countries","volume":"30","author":"Fokam","year":"2024","journal-title":"Nat Med"},{"key":"2025073007425481100_jiaf196-B16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/QAI.0000000000002496","article-title":"Review of doravirine resistance patterns identified in participants during clinical development","volume":"85","author":"Martin","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025073007425481100_jiaf196-B17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1358\/dot.2020.56.2.3109966","article-title":"Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection","volume":"56","author":"Talwani","year":"2020","journal-title":"Drugs Today"},{"key":"2025073007425481100_jiaf196-B18","doi-asserted-by":"crossref","first-page":"2020-5-9","DOI":"10.7573\/dic.2020-5-9","article-title":"Potential risk of drug\u2013drug interactions with hormonal contraceptives and antiretrovirals: prevalence in women living with HIV","volume":"9","author":"Murray","year":"2020","journal-title":"Drugs Context"},{"key":"2025073007425481100_jiaf196-B19","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1517\/17425255.2013.772579","article-title":"Drug interactions between antiretrovirals and hormonal contraceptives","volume":"9","author":"Tseng","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025073007425481100_jiaf196-B20","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s40262-019-00806-9","article-title":"Clinical pharmacodynamics, pharmacokinetics, and drug interaction profile of doravirine","volume":"58","author":"Boyle","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2025073007425481100_jiaf196-B21","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1097\/QAD.0000000000003514","article-title":"Inclusion of women in HIV research and clinical trials","volume":"37","author":"Johnston","year":"2023","journal-title":"AIDS"},{"key":"2025073007425481100_jiaf196-B22","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/cid\/ciy540","article-title":"Doravirine\/lamivudine\/tenofovir disoproxil fumarate is non-inferior to efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus\u20131 infection: week 48 results of the DRIVE-AHEAD trial","volume":"68","author":"Orkin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025073007425481100_jiaf196-B23","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/S2352-3018(18)30021-3","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"2025073007425481100_jiaf196-B24","doi-asserted-by":"crossref","first-page":"e13721","DOI":"10.1111\/cts.13721","article-title":"Bidirectional pharmacokinetics of doravirine, tenofovir, and feminizing hormones in transgender women (IDentify): a randomized crossover trial","volume":"17","author":"Lam","year":"2024","journal-title":"Clin Transl Sci"},{"key":"2025073007425481100_jiaf196-B25","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1097\/QAD.0000000000002308","article-title":"A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda","volume":"33","author":"Patel","year":"2019","journal-title":"AIDS"},{"key":"2025073007425481100_jiaf196-B26","doi-asserted-by":"crossref","first-page":"e01298-19","DOI":"10.1128\/AAC.01298-19","article-title":"Doravirine exposure and HIV-1 suppression after switching from an efavirenz-based regimen to doravirine\/lamivudine\/tenofovir disoproxil fumarate","volume":"63","author":"Greaves","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025073007425481100_jiaf196-B27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.contraception.2018.01.015","article-title":"Simultaneous quantitation of multiple contraceptive hormones in human serum by LC-MS\/MS","volume":"97","author":"Blue","year":"2018","journal-title":"Contraception"},{"author":"Patel","key":"2025073007425481100_jiaf196-B28"},{"key":"2025073007425481100_jiaf196-B29","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.1016\/S2352-3018(24)00150-4","article-title":"ATHENA National Observational Cohort Study. Real-world effectiveness and tolerability of switching to doravirine-based antiretroviral therapy in people with HIV: a nationwide, matched, prospective cohort study","volume":"11","author":"Oomen","year":"2024","journal-title":"Lancet HIV"},{"author":"World Health Organization (WHO).","key":"2025073007425481100_jiaf196-B30"},{"key":"2025073007425481100_jiaf196-B31","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S2352-3018(23)00258-8","article-title":"Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials","volume":"11","author":"Orkin","year":"2024","journal-title":"Lancet HIV"},{"key":"2025073007425481100_jiaf196-B32","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/14740338.2021.1887135","article-title":"Risks and benefits of reducing the number of drugs to treat HIV-1 infection","volume":"20","author":"Cadi\u00f1anos","year":"2021","journal-title":"Expert Opin Drug Saf"},{"author":"Do","key":"2025073007425481100_jiaf196-B33"},{"author":"Joint United Nations Programme on HIV\/AIDS (UNAIDS)","key":"2025073007425481100_jiaf196-B34"},{"key":"2025073007425481100_jiaf196-B35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1742-6405-10-30","article-title":"Women and HIV in sub-Saharan Africa","volume":"10","author":"Ramjee","year":"2013","journal-title":"AIDS Res Ther"},{"author":"Joint United Nations Programme on HIV\/AIDS (UNAIDS)","key":"2025073007425481100_jiaf196-B36"},{"key":"2025073007425481100_jiaf196-B37","doi-asserted-by":"crossref","first-page":"e0195499","DOI":"10.1371\/journal.pone.0195499","article-title":"Optimizing adherence in HIV prevention product trials: development and psychometric evaluation of simple tools for screening and adherence counseling","volume":"13","author":"Tolley","year":"2018","journal-title":"PLoS One"},{"key":"2025073007425481100_jiaf196-B38","doi-asserted-by":"crossref","first-page":"e522","DOI":"10.1016\/S2352-3018(24)00125-5","article-title":"Impact of a point-of-care urine tenofovir assay on adherence to HIV pre-exposure prophylaxis among women in Kenya: a randomised pilot trial","volume":"11","author":"Gandhi","year":"2024","journal-title":"Lancet HIV"},{"key":"2025073007425481100_jiaf196-B39","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2468-2667(21)00112-2","article-title":"HIV pre-exposure prophylaxis: scaling up for impact now and in the future","volume":"6","author":"Bavinton","year":"2021","journal-title":"Lancet Public Health"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf196\/62942345\/jiaf196.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/1\/79\/62942345\/jiaf196.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/1\/79\/62942345\/jiaf196.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:42:59Z","timestamp":1753875779000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/232\/1\/79\/8114927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,4,22]]},"published-print":{"date-parts":[[2025,7,30]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf196","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"type":"print","value":"0022-1899"},{"type":"electronic","value":"1537-6613"}],"subject":[],"published-other":{"date-parts":[[2025,7,15]]},"published":{"date-parts":[[2025,4,22]]}}}